Evidence map›Paper›PMID 34503146›Full record

ArticleCancers2021

A Three-Domain Scoring System to Customize the Risk of Relapse of Differentiated Thyroid Carcinoma.

Arnoldo Piccardo, Giacomo Siri, Martina Ugolini, Francesco Fiz, Matteo Puntoni, Gianluca Bottoni, Ugo Catrambone, Fabián Pitoia, Pierpaolo Trimboli

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Arnoldo PiccardoDepartment of Nuclear Medicine, E.O. "Ospedali Galliera", 16128 Genoa, Italy.ORCID 0000-0002-6779-1471
Giacomo SiriScientific Directorate, Galliera Hospital, 16128 Genoa, Italy.
Martina UgoliniDepartment of Nuclear Medicine, E.O. "Ospedali Galliera", 16128 Genoa, Italy.
Francesco FizDepartment of Nuclear Medicine, E.O. "Ospedali Galliera", 16128 Genoa, Italy.
Matteo PuntoniClinical & Epidemiological Research Unit, University Hospital of Parma, 43126 Parma, Italy.ORCID 0000-0002-7908-0626
Gianluca BottoniDepartment of Nuclear Medicine, E.O. "Ospedali Galliera", 16128 Genoa, Italy.ORCID 0000-0003-4150-0266
Ugo CatramboneDepartment of Surgery, E.O. "Ospedali Galliera", 16128 Genoa, Italy.
Fabián PitoiaDivision of Endocrinology, Hospital de Clínicas, University of Buenos Aires, Buenos Aires C1053, Argentina.
Pierpaolo TrimboliServizio di Endocrinologia e Diabetologia, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale (EOC), 6900 Lugano, Switzerland.ORCID 0000-0002-2125-4937
Ente Ospedaliero Ospedali Galliera · ITOspedale regionale di Lugano · CHUniversidad de Buenos Aires · ARUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposethe validation of a new scoring model considering the principal risk factors of differentiated thyroid cancer (DTC) relapse.

methodswe evaluated all DTC patients treated with thyroidectomy and radioactive iodine (RAI) therapy. Three domains were considered: the demographic domain (age and gender), the surgical domain (histology and the American Thyroid Association risk categories), and the RAI-related domain (pre-RAI thyroglobulin and post-therapeutic

results907 DTC patients were included. The RAI-related domain was the most relevant factor in the score calculation. The tercile stratification identified significantly different survival curves: patients within the two upper terciles showed approximately 6 to 30 times more progressive risk than patients at mild risk.

conclusionwe have validated a three-domain scoring system and the principal impact on this score is provided by the peri-RAI findings, whose prognostic role seems to be essential in risk identification.

Indexed as

domainsDTCpost-therapeutic 131-I-WBSpre-RAI TgRAIscoring system

Identifiers

PMID34503146
PMCPMC8430463
OpenAlexW3197191363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.